{"id":"F2021L01167","name":"Statement of Principles concerning carpal tunnel syndrome (Reasonable Hypothesis) (No. 93 of 2021)","slug":"statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":440971,"registerId":"F2021L01167-fast-fetch-1775956408733","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning carpal tunnel syndrome (Reasonable Hypothesis) (No. 93 of 2021)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nCARPAL TUNNEL SYNDROME (Reasonable Hypothesis)\n\n(No. 93 of 2021)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 20 August 2021\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning carpal tunnel syndrome (Reasonable Hypothesis) (No. 93 of 2021).\n\n2 Commencement\n\n This instrument commences on 20 September 2021.\n\n3 Authority\n\nThis instrument is made under subsection 196B(2) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning carpal tunnel syndrome No. 7 of 2013 (Federal Register of Legislation No. F2013L00022) made under subsection 196B(2) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about carpal tunnel syndrome and death from carpal tunnel syndrome.\n\nMeaning of carpal tunnel syndrome\n\n(2) For the purposes of this Statement of Principles, carpal tunnel syndrome means an entrapment neuropathy of the median nerve at the wrist producing altered sensation, pain or weakness of the hand.\n\n(3) While carpal tunnel syndrome attracts ICD‑10‑AM code G56.0, in applying this Statement of Principles the meaning of carpal tunnel syndrome is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from carpal tunnel syndrome\n\n(5) For the purposes of this Statement of Principles, carpal tunnel syndrome, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's carpal tunnel syndrome.\n\nNote: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nThe Repatriation Medical Authority is of the view that there is sound medical‑scientific evidence that indicates that carpal tunnel syndrome and death from carpal tunnel syndrome can be related to relevant service rendered by veterans, members of Peacekeeping Forces, or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised connecting carpal tunnel syndrome or death from carpal tunnel syndrome with the circumstances of a person's relevant service:\n\n(1) performing any combination of specified activities with the affected hand or forearm:\n\n(a) for an average of at least 8 hours per week; and\n\n(b) for a cumulative period of at least 6 months before the clinical onset of carpal tunnel syndrome; and\n\nif those activities have ceased before the clinical onset of carpal tunnel syndrome, then that onset occurred within 30 days of cessation;\n\nNote: specified activities with the affected hand or forearm is defined in the Schedule 1 - Dictionary.\n\n(2) having trauma or surgery to the affected wrist or hand before the clinical onset of carpal tunnel syndrome, which:\n\n(a) alters the normal contour of the carpal tunnel; or\n\n(b) damages the flexor tendons within the carpal tunnel;\n\nNote: trauma to the affected wrist or hand is defined in the Schedule 1 - Dictionary.\n\n(3) having oedema involving the affected carpal tunnel at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: Examples of situations in which oedema involving the affected carpal tunnel may occur include external burn, fracture, lymphoedema and animal envenomation.\n\n(4) being overweight or obese at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: being overweight or obese is defined in the Schedule 1 - Dictionary.\n\n(5) having amyloidosis at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: amyloidosis is defined in the Schedule 1 - Dictionary.\n\n(6) having chronic renal failure at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: chronic renal failure is defined in the Schedule 1 - Dictionary.\n\n(7) having hypothyroidism or Hashimoto thyroiditis at the time of the clinical onset of carpal tunnel syndrome;\n\n(8) having acromegaly before the clinical onset of carpal tunnel syndrome;\n\nNote: acromegaly is defined in the Schedule 1 - Dictionary.\n\n(9) having gout involving the affected wrist or hand at the time of the clinical onset of carpal tunnel syndrome;\n\n(10) having a space-occupying lesion in the affected carpal tunnel at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: Examples of a space-occupying lesion include neoplasm, ganglion, tenosynovitis and muscle intrusion.\n\n(11) having haemorrhage involving the affected carpal tunnel at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: Examples of situations in which haemorrhage involving the affected carpal tunnel may occur include haemophilia, von Willebrand’s disease and taking anticoagulants.\n\n(12) having infection involving the affected carpal tunnel at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: Examples of infections that may involve the carpal tunnel include histoplasmosis, tuberculosis and chikungunya fever.\n\n(13) having osteoarthritis or inflammatory arthritis involving the affected wrist or hand at the time of the clinical onset of carpal tunnel syndrome;\n\nNote: inflammatory arthritis is defined in the Schedule 1 - Dictionary.\n\n(14) having diabetes mellitus at the time of the clinical onset of carpal tunnel syndrome;\n\n(15) taking an aromatase inhibitor within the 2 years before the clinical onset of carpal tunnel syndrome;\n\nNote: Examples of aromatase inhibitors include anastrozole, exemestane and letrozole.\n\n(16) taking an immune checkpoint inhibitor within the 2 years before the clinical onset of carpal tunnel syndrome;\n\nNote: Examples of immune checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab and avelumab.\n\n(17) being pregnant within the 3 months before the clinical onset of carpal tunnel syndrome;\n\n(18) performing any combination of specified activities with the affected hand or forearm:\n\n(a) for an average of at least 8 hours per week; and\n\n(b) for a cumulative period of at least 6 months before the clinical worsening of carpal tunnel syndrome; and\n\nif those activities have ceased before the clinical worsening of carpal tunnel syndrome, then that worsening occurred within 30 days of cessation;\n\nNote: specified activities with the affected hand or forearm is defined in the Schedule 1 - Dictionary.\n\n(19) having trauma or surgery to the affected wrist or hand before the clinical worsening of carpal tunnel syndrome, which:\n\n(a) alters the normal contour of the carpal tunnel; or\n\n(b) damages the flexor tendons within the carpal tunnel;\n\nNote: trauma to the affected wrist or hand is defined in the Schedule 1 - Dictionary.\n\n(20) having oedema involving the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: Examples of situations in which oedema involving the affected carpal tunnel may occur include external burn, fracture, lymphoedema and animal envenomation.\n\n(21) being overweight or obese at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: being overweight or obese is defined in the Schedule 1 - Dictionary.\n\n(22) having amyloidosis at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: amyloidosis is defined in the Schedule 1 - Dictionary.\n\n(23) having chronic renal failure at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: chronic renal failure is defined in the Schedule 1 - Dictionary.\n\n(24) having hypothyroidism or Hashimoto thyroiditis at the time of the clinical worsening of carpal tunnel syndrome;\n\n(25) having acromegaly before the clinical worsening of carpal tunnel syndrome;\n\nNote: acromegaly is defined in the Schedule 1 - Dictionary.\n\n(26) having gout involving the affected wrist or hand at the time of the clinical worsening of carpal tunnel syndrome;\n\n(27) having a space-occupying lesion in the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: Examples of a space-occupying lesion include neoplasm, ganglion, tenosynovitis and muscle intrusion.\n\n(28) having haemorrhage involving the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: Examples of situations in which haemorrhage involving the affected carpal tunnel may occur include haemophilia, von Willebrand’s disease and taking anticoagulants.\n\n(29) having infection involving the affected carpal tunnel at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: Examples of infections that may involve the carpal tunnel include histoplasmosis, tuberculosis and chikungunya fever.\n\n(30) having osteoarthritis or inflammatory arthritis involving the affected wrist or hand at the time of the clinical worsening of carpal tunnel syndrome;\n\nNote: inflammatory arthritis is defined in the Schedule 1 - Dictionary.\n\n(31) having diabetes mellitus at the time of the clinical worsening of carpal tunnel syndrome;\n\n(32) taking an aromatase inhibitor within the 2 years before the clinical worsening of carpal tunnel syndrome;\n\nNote: Examples of aromatase inhibitors include anastrozole, exemestane and letrozole.\n\n(33) taking an immune checkpoint inhibitor within the 2 years before the clinical worsening of carpal tunnel syndrome;\n\nNote: Examples of immune checkpoint inhibitors include pembrolizumab, nivolumab, ipilimumab and avelumab.\n\n(34) being pregnant within the 3 months before the clinical worsening of carpal tunnel syndrome;\n\n(35) inability to obtain appropriate clinical management for carpal tunnel syndrome.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(18) to 9(35) apply only to material contribution to, or aggravation of, carpal tunnel syndrome where the person's carpal tunnel syndrome was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(2) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n acromegaly means a chronic disease of adults resulting from hypersecretion of growth hormone after closure of the epiphyses.\n\n amyloidosis means the accumulation of insoluble fibrillar proteins in organs or tissues of the body such that vital function is compromised.\n\nNote: Diseases that can be associated with amyloidosis include myeloma and chronic inflammatory diseases or chronic infectious diseases, such as inflammatory bowel disease, rheumatoid arthritis and tuberculosis.\n\n being overweight or obese means:\n\n(a) having a Body Mass Index (BMI) of 25 or greater; or\n\n(b) for males, having a waist circumference exceeding 94 centimetres; or\n\n(c) for females, having a waist circumference exceeding 80 centimetres.\n\n \n\nNote: BMI is also defined in the Schedule 1 - Dictionary.\n\n BMI means W/H2 where:\n\n(a) W is the person's weight in kilograms; and\n\n(b) H is the person's height in metres.\n\n carpal tunnel syndrome—see subsection 7(2).\n\n chronic renal failure means:\n\n(a) having a glomerular filtration rate of less than 15 mL/min/1.73 m2 for a period of at least three months; or\n\n(b) a need for renal replacement therapy (dialysis or transplantation) for treatment of complications of decreased glomerular filtration rate which would otherwise increase the risk of morbidity and mortality; or\n\n(c) undergoing chronic dialysis.\n\n inflammatory arthritis means an autoimmune inflammatory disease which is associated with the development of arthritis.\n\nNote: Types of inflammatory arthritis include rheumatoid arthritis, systemic sclerosis, Sjögren syndrome, sarcoidosis, and other inflammatory arthritis requiring treatment with a disease modifying agent or a biological agent.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n relevant service means:\n\n(a) operational service under the VEA;\n\n(b) peacekeeping service under the VEA;\n\n(c) hazardous service under the VEA;\n\n(d) British nuclear test defence service under the VEA;\n\n(e) warlike service under the MRCA; or\n\n(f) non-warlike service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n specified activities with the affected hand or forearm means:\n\n(a) repetitive activities using the affected hand, involving either:\n\n(i) bending or twisting of the hand or wrist at least 50 times per hour; or\n\n(ii) carrying out the same or similar movements in the hand or wrist at least 50 times per hour; or\n\n(b) forceful activities requiring the generation of force by the affected hand:\n\n(i) equivalent to lifting or carrying loads of more than 3 kilograms; or\n\n(ii) involving lifting or carrying an object in the hand greater than 1 kilogram in excess of 10 times per hour; or\n\n(c) activities where the affected hand or forearm is directly vibrated; or\n\n(d) activities where the affected hand is used for weight-bearing.\n\nNote 1: Forceful activities requiring generation of force by the hand include the use of crutches or other walking aids and hand propulsion of wheelchairs.\n\nNote 2: Activities where the hand may be used for weight-bearing include transfers from a wheelchair to a chair or bed, and the use of crutches or other walking aids.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n trauma to the affected wrist or hand means a discrete event involving the application of significant physical force to or through the affected wrist or hand, that causes:\n\n(a) damage to the wrist or hand; and\n\n(b) the development, within 24 hours of the event occurring, of symptoms and signs of pain and tenderness, and either altered mobility or range of movement of the wrist or hand. In the case of sustained unconsciousness or the masking of pain by analgesic medication, these symptoms and signs must appear on return to consciousness or the withdrawal of the analgesic medication; and\n\n(c) the persistence of these symptoms and signs for a period of at least 7 days following their onset, save for where medical intervention for the trauma to that wrist or hand has occurred and that medical intervention involves one of the following:\n\n(i) immobilisation of the wrist or hand by splinting or similar external agent;\n\n(ii) injection of a corticosteroid or local anaesthetic into that wrist or hand; or\n\n(iii) surgery to that wrist or hand.\n\nNote: Examples of trauma include laceration, sprain, crush injury, fracture, dislocation, and a thermal, electrical or chemical burn.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":true,"description":"This instrument replaces the earlier 2013 Statement of Principles for carpal tunnel syndrome (section 4) and expands the operational scope in several specific ways: (a) it sets explicit quantitative exposure thresholds for repetitive/forceful hand use (8 hours/week; cumulative 6 months; 50 movements/hour or weight criteria) where earlier instruments were often more qualitative (see section 9 and Schedule 1 'specified activities'); (b) it lists additional medical contributors and drug exposures (notably aromatase inhibitors and immune checkpoint inhibitors in sections 9(15) and 9(16)); (c) it expressly treats both clinical onset and clinical worsening/material contribution with largely parallel factor lists (sections 9(1) and 9(18)–9(35)); and (d) it adds non-clinical procedural factors such as inability to obtain appropriate clinical management as a potential factor for worsening (section 9(35)). These changes broaden the set of circumstances that can raise a reasonable hypothesis of service connection and increase the granularity of evidentiary expectations for claimants and decision-makers."},"complexity_factors":["Single subject-focused instrument with 11 operative sections and a Schedule (moderate length).","35 enumerated factors in section 9 (many duplicated for onset and for clinical worsening).","Multiple quantitative thresholds and temporal conditions (e.g. >=8 hours/week average; cumulative >=6 months; 30-day cessation rule).","Around 15 defined terms and medical definitions in Schedule 1 (e.g. BMI, chronic renal failure, acromegaly, amyloidosis, specified activities).","Cross-references to other RMA Statements of Principles (section 11) creating interdependence.","Conditional logic distinguishing onset vs. worsening vs. material contribution (section 10 and section 9(18)–(35)).","Technical medical concepts and drug classes included (e.g. immune checkpoint inhibitors, aromatase inhibitors) requiring clinical verification.","Inclusion of both objective measures (BMI, GFR) and contextual evidence (work activity histories) increases evidentiary heterogeneity.","Repeal and replacement of an earlier Statement (administrative continuity considerations)."],"plain_english_summary":"**What this instrument does (mechanically)\n\n- Replaces the earlier Statement of Principles for carpal tunnel syndrome and sets the Repatriation Medical Authority's (RMA) rules for when a reasonable hypothesis exists that a veteran’s carpal tunnel syndrome (CTS) — or death contributed to by CTS — is connected to their military service (see sections 3, 4, 7 and 9).\n- Specifies the medical meaning of \"carpal tunnel syndrome\" for claims purposes (an entrapment neuropathy of the median nerve at the wrist producing altered sensation, pain or weakness) and notes the ICD‑10‑AM code but relies on its own definition (section 7).\n- Lists the specific factors (medical conditions, injuries, workplace activities, drug exposures, pregnancy, etc.) that must be present to raise a reasonable hypothesis linking CTS to relevant service (section 9 and Schedule 1 dictionary).\n- Sets quantitative exposure thresholds for occupational-type activities (an average of at least 8 hours per week, for a cumulative 6 months, with a 30‑day rule if the activities stopped before onset/worsening) and defines what counts as \"specified activities\" (Schedule 1).\n- Treats both: (a) factors that can be relevant to the clinical onset of CTS; and (b) largely the same set of factors that can materially contribute to or aggravate an existing CTS (separate lists for onset and for clinical worsening) (sections 9(1) and 9(18)–9(35)).\n- Cross-references other Statements of Principles where a listed factor is itself an injury or disease already covered by another RMA statement (section 11).\n\nWho it affects\n\n- Veterans and former members of the Australian Defence Forces (and certain peacekeeping/other categories listed as \"relevant service\") who lodge claims under the Veterans' Entitlements Act 1986 (VEA) or the Military Rehabilitation and Compensation Act 2004 (MRCA) for CTS or death contributed to by CTS (section 5, Schedule 1 definitions).\n- Medical practitioners, claims officers and administrators who must apply these specific criteria when deciding whether a \"reasonable hypothesis\" exists that links an individual's CTS to their service.\n\nWhy it matters (stated purpose, and practical consequences)\n\n- The RMA states that there is sound medical-scientific evidence linking CTS and death contributed to by CTS to service (section 8). The instrument operationalises that claim by prescribing the concrete factors and evidentiary thresholds that will satisfy the \"reasonable hypothesis\" test used in the administration of veterans' claims.\n\nPractical effects, incentives and administrative implications\n\n- Who pays and who decides: If a claim meets the reasonable-hypothesis threshold according to these criteria, the Department/agency responsible for veterans' entitlements proceeds with the claim process under the VEA/MRCA. The RMA sets the medical rules; claims staff and clinicians apply them.\n- Evidence and documentation burden: Claimants (or their clinicians) must show that one or more listed factors existed at the relevant time—examples include medical records for trauma/surgery, BMI or waist measurements, diagnostic evidence for diabetes or renal failure, drug prescription history for specified drug classes, or work/exposure histories documenting the specified activity thresholds. The instrument therefore creates concrete evidentiary expectations (sections 9, Schedule 1).\n- Quantified exposure rules: The inclusion of specific time and intensity thresholds for repetitive or forceful hand/forearm activities (8 hours/week; cumulative 6 months; 50 movements/hour or defined weight criteria) makes some causation findings more mechanical and may reduce disputed, purely qualitative assessments (section 9(1) and Schedule 1 \"specified activities\").\n- Medical comorbidities and drug exposures: The instrument lists many clinical conditions and treatment exposures (e.g. diabetes, chronic renal failure, amyloidosis, hypothyroidism, acromegaly, gout, space-occupying lesions, haemorrhage, infection, aromatase inhibitors, immune checkpoint inhibitors, pregnancy) as potential causal or aggravating factors; claimants with these conditions will rely on those entries when linking CTS to service (section 9 and Schedule 1 definitions).\n- Dual coverage for onset and worsening: The instrument separately addresses factors that can cause CTS to begin and factors that can materially contribute to or worsen pre-existing CTS — affecting how claims are assessed when CTS existed before service (section 10 and 9(18)–9(35)).\n\nTrade-offs, risks and likely administrative consequences\n\n- Administrative predictability vs. evidentiary burden: The numeric thresholds and defined list of medical factors increase predictability for decision-makers, but they raise documentary requirements for claimants (medical records, objective measurements, employment logs). That shifts costs partly onto claimants and treating clinicians (compliance/records) and onto administrators required to verify them.\n- Scope of entitlement and fiscal exposure: Adding many recognised medical contributors (and specifying pharmaceutical agents and pregnancy windows) can broaden the base of claims that pass the \"reasonable hypothesis\" test, with downstream cost implications for the compensation system.\n- Implementation discretion: While the Statement is detailed, some judgment remains — e.g. whether a claimant's reported hand use meets the defined thresholds, whether a listed comorbidity was present at the relevant time, or whether clinical management was \"appropriate\" (section 9(35) refers to inability to obtain appropriate clinical management). Such assessments leave room for case-by-case discretion and potential dispute.\n- Interaction with other RMA Statements: Where a listed factor is itself a disease covered by another Statement, that other Statement's factors apply. This creates interdependency across RMA instruments and requires cross-checking (section 11).\n\nConcrete behavioural effects\n\n- Claimant behaviour: Individuals with listed risk factors, exposures or medication histories are more likely to lodge claims because the instrument makes it clearer which circumstances raise a reasonable hypothesis of service connection.\n- Clinical/practice behaviour: Treating practitioners may be asked to document objective measures (BMI, GFR, surgical/trauma records, drug prescriptions, employment exposure notes) that they might not previously have routinely recorded for non-service purposes.\n- Employer/record-keeping effects: Where service-related work involved repetitive or forceful hand use, precise record-keeping (duty statements, rosters, equipment records) becomes more important to substantiate the required exposure thresholds.\n\nKey provisions to consult when applying the Statement\n\n- Definition of CTS and death from CTS: section 7.\n- List of required factors and exposure thresholds: section 9; Schedule 1 for definitions (including \"specified activities\", BMI, trauma, chronic renal failure, etc.).\n- Relationship-to-service rules and how worsening of pre-existing CTS is treated: section 10.\n- Cross-reference rule for factors covered by other Statements: section 11.\n\nSource claim and testing against costs and incentives\n\n- The RMA claims medical evidence supports service connections (section 8). Accepting that, the instrument operationalises the claim by enumerating specific clinical and exposure conditions that will satisfy the \"reasonable hypothesis\" standard. The trade-offs are clear: greater certainty for claims examiners and claimants prepared to document the listed factors, at the cost of increased evidentiary requirements and potential expansion of the universe of acceptable claims (which has budgetary and administrative consequences)."},"flash_summary_failed":{"failed":true,"reason":"Unauthenticated. Configure AI_GATEWAY_API_KEY or use a provider module. Learn more: https://ai-sdk.dev/unauthenticated-ai-gateway","source":"analysis-cron"},"kimi_summary":{"content_quality":"ok","complexity_score":5,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It replaces the 2013 version (No. 7 of 2013) with updated medical factors but does not expand beyond the traditional function of establishing service-related causation for a specific condition. The structure mirrors standard RMA practice: defining the condition, listing onset and aggravation factors, and providing technical definitions. While the specific medical factors have been modernised (adding immune checkpoint inhibitors and aromatase inhibitors, for example), the legislative scope remains confined to determining compensation eligibility for carpal tunnel syndrome under veterans' legislation."},"complexity_factors":["35 distinct factors with parallel structure (factors 1-17 for onset, 18-34 for worsening, 35 for clinical management)","Multiple defined terms in Schedule 1 (approximately 12 formal definitions including nested definitions like 'being overweight or obese' which itself references BMI)","Cross-references to external legislation (VEA and MRCA) and medical classification systems (ICD-10-AM)","Conditional timing requirements throughout (e.g., 'within 30 days of cessation', 'within 2 years before', 'within 3 months before')","Nested definitional complexity in 'trauma to the affected wrist or hand' requiring 3 cumulative elements with an exception sub-clause containing 3 further alternatives","Incorporation by reference of other Statements of Principles (section 11) creating interdependence with unknown external instruments","Dual application framework distinguishing between 'clinical onset' and 'clinical worsening' with different legal consequences (section 10(2))"],"plain_english_summary":"This Statement of Principles sets the medical rules for deciding whether current or former Australian Defence Force members, veterans and peacekeepers can get compensation for carpal tunnel syndrome. It identifies 35 service‑related medical or activity factors — e.g. repetitive forceful wrist/hand use, trauma, or related medical conditions — where the presence of at least one, linked to service, creates a \"reasonable hypothesis\" of causation.\n\nIt replaces the 2013 version and eases claims by using the lower \"reasonable hypothesis\" threshold to establish a service connection."}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021","history":"/api/acts/statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021/history","analysis":"/api/acts/statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021/analysis","conflicts":"/api/acts/statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021/important-cases","documents":"/api/acts/statement-of-principles-concerning-carpal-tunnel-syndrome-reasonable-hypothesis-no-93-of-2021/documents"}}